Credit: Pixabay.
Tens of millions of Americans have been infected with the virus thus far. But although the vast majority have recovered, long-term complications related to COVID-19 may continue to put their lives at risk. A new study that examined over 87,000 patients found that COVID-19 survivors had an almost 60% increased risk of death over the following six months compared with the general population.
“Our study demonstrates that up to six months after diagnosis, the risk of death following even a mild case of COVID-19 is not trivial and increases with disease severity,” said senior author Ziyad Al-Aly, MD, an assistant professor at the Washington University School of Medicine. “It is not an exaggeration to say that long COVID-19 the long-term health consequences of COVID-19 is America’s next big health crisis. Given that more than 30 million Americans have been infected with this virus, and given that the burden of long COVID-19 is substantial, the lingering effe
Share this article
Share this article
NEW YORK, May 14, 2021 /PRNewswire/ Researchers have discovered new ways in which the COVID-19 virus causes human immune cells to overreact, a deadly part of the disease.
Led by researchers from NYU Grossman School of Medicine and the Perlmutter Cancer Center at NYU Langone Health, the new study found that SARS-CoV-2, the pandemic virus, interacts with specific proteins on immune cells, causing these cells to release abnormally high levels of immune signaling proteins called cytokines (a cytokine storm ). These cytokines, in turn, cause fluid buildup in the lungs and makes it hard to breathe.
As part of All of Us Research Program, School of Medicine will seek to enroll local participants
May 12, 2021 SHARE Washington University School of Medicine in St. Louis has joined the All of Us Research Program, an initiative of the National Institutes of Health (NIH) that seeks to recruit 1 million volunteers to build a detailed biomedical data resource that reflects the breadth and diversity of the U.S. population. Washington University will help enroll participants who represent the rich diversity of the St. Louis region. (Photo: Getty Images)
To help understand the complex factors that contribute to human health and disease, Washington University School of Medicine in St. Louis has joined the All of Us Research Program, an initiative of the National Institutes of Health (NIH) that seeks to build a large, detailed biomedical data resource that reflects the breadth and diversity of the U.S. population.
E-Mail
Multiple studies have shown that African American women with breast cancer have lower survival rates than white women with the disease. But the association between race or ethnicity and treatment outcomes in triple-negative breast cancer an aggressive type of tumor that does not respond to hormonal or other targeted therapies has not been well defined.
Now, new research from Washington University School of Medicine in St. Louis shows that non-Hispanic African American women with triple-negative breast cancer also do not fare as well as non-Hispanic white women with this type of breast cancer. The study demonstrates the need for additional research to address disparities in cancer care and understand whether tumor biology or nonbiological reasons such as systemic racism or a combination of such factors may prevent African American women from receiving the same quality of care as white women.
Getty Images
A new study from Washington University School of Medicine in St. Louis shows that African American women with triple-negative breast cancer have higher mortality than white American women with this aggressive tumor. The investigators call for more research to understand the factors driving the disparities in order to find ways to address them.
Multiple studies have shown that African American women with breast cancer have lower survival rates than white women with the disease. But the association between race or ethnicity and treatment outcomes in triple-negative breast cancer an aggressive type of tumor that does not respond to hormonal or other targeted therapies has not been well defined.